Compounded GLP-1 legality by ZIP code

How does compounding law actually work in 2026?

Compounding is governed by federal law first. Section 503A of the Food, Drug, and Cosmetic Act covers traditional pharmacies filling patient-specific prescriptions. Section 503B covers outsourcing facilities that register with the FDA and meet current good manufacturing practice standards. Both categories can produce compounded semaglutide or tirzepatide when the clinical reasoning is documented.

The FDA ended the semaglutide shortage on February 18, 2025, and the tirzepatide shortage in December 2024. That killed the broad shortage-based compounding route. Compounders still produce these drugs, but only under the patient-specific clinical-need path: documented intolerance to a brand-name ingredient, need for a different dosage form, or allergies to an inactive ingredient.

States add their own layer. Your state board of pharmacy can require extra labeling, restrict telehealth-only prescribing, or set limits on how a pharmacy sources bulk API. That's why two ZIPs in different states can return very different answers.

State-by-state table

What should you check before ordering?

Three things, in order. One, confirm the dispensing pharmacy's license in your state. Every state board publishes a verification tool. Two, ask whether the pharmacy is 503A (patient-specific) or 503B (FDA-registered outsourcing). 503B facilities publish facility IDs on the FDA list and undergo routine inspections. Three, request the certificate of analysis for the active ingredient. A legitimate compounder ships a COA on request.

None of that guarantees quality, but any pharmacy that refuses those three asks isn't one you want near your injection schedule.

Frequently asked questions